QGEN QIAGEN N.V.

QIAGEN N.V. to release results for Q1 2024 and hold webcast

QIAGEN N.V. to release results for Q1 2024 and hold webcast

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.

Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. 

Three options for joining the conference call

Register for call back connection - Click here:

Service is available 15 minutes before the call starts 

Dial-in by phone

U.S.:

UK: +44 (0)330 165 3655

GER: +49 (0)69 6610 2492

Conference ID: 2903795

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. 

Access the audio webcast - Click here:

 A conference call replay will be available by using the following link:

  

Contact:  

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

As of December 31, 2023, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. 



Further information can be found at . 

source: QIAGEN N.V. 

category: Financial  

 



John Gilardi
QIAGEN N.V.
 11
 

Domenica Martorana
QIAGEN N.V.
 44
 
EN
09/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QIAGEN N.V.

 PRESS RELEASE

QIAGEN N.V. to release results for Q2 2024 and hold webcast

QIAGEN N.V. to release results for Q2 2024 and hold webcast Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Service i...

 PRESS RELEASE

QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plu...

QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today ...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

QIAGEN announces 2028 strategy for solid profitable growth

QIAGEN announces 2028 strategy for solid profitable growth Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization // Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $1 billion to shareholders Venlo, th...

 PRESS RELEASE

QIAGEN’s software QCI Interpret accelerates clinical reporting turnaro...

QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows // Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalability Venlo, the Netherlands, and Redwood City, California, Ju...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch